The Proton-Pump MDL 2789 lawsuits are being adjudicated upon by Judge Claire Cecchi and Judge Mark Falk in the United States District Court of New Jersey.
In February 2017 the U.S. Judicial Panel on Multidistrict Litigation denied motion to combine 39 federal lawsuits against various PPI manufacturers into a single MDL.
In 2015, scientific studies revealed that patients over 66 faced a two-fold risk of acute kidney injury from long-term PPI use.
- Other studies showed a 1.16-fold increase in heart attack risk and double the risk of cardiovascular mortality when compared to patients taking
H2 blockers for heartburn relief
- Additional studies from Johns Hopkins University and the American Society of Nephrology linked long-term PPI use with a 20-50% increased risk of chronic kidney disease (CKD) and a 96% increased risk of kidney failure
- PPIs Named in Lawsuits & Manufacturers Being Sued:
In 2015, AstraZeneca settled a lawsuit for allegedly participating in a kickback scheme.
In 2013, AtraZeneca settled a class action lawsuit before trial when plaintiffs claimed AstraZeneca deceptively marketed Nexium as a superior acid reflux treatment, causing consumers to pay nearly 8x more instead of using the cheaper, equally effective generic version.
- To avoid trial, AstraZeneca eventually paid $20 million to plaintiffs who purchased Nexium between March 1, 2001 and February 6, 2013.